Subscribe
shutterstock_2026137224_flowersandtraveling
Flowersandtraveling / Shutterstock.com
20 September 2022Big PharmaMuireann Bolger

Pharma company hit with racial discrimination lawsuit

Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pfizer sued over COVID-19 antiviral drug
28 June 2022   Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.
Generics
Pfizer sues MSN Labs over Xeljanz generic
9 June 2022   Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.


Editor's picks

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025

Editor's picks

Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025
Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025

More features

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
Why AI is changing the patent rules faster than anyone can keep up
The hidden code in life sciences deals
LSPN panel unpacks critical IP risks in deal-making
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
Less is more: patent lawyers flip the script after Amgen
‘Doing more with less’: In-house counsel on budgets and strategy
End of the ‘Death Squad’? Squires puts PTAB on trial